The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02C | Antimigraine preparations | |
| 4 | N02CA | Ergot alkaloids |
| Code | Title | |
|---|---|---|
| N02CA01 | Dihydroergotamine | |
| N02CA02 | Ergotamine | |
| N02CA04 | Methysergide | |
| N02CA07 | Lisuride | |
| N02CA51 | Dihydroergotamine, combinations | |
| N02CA52 | Ergotamine, combinations excl. psycholeptics | |
| N02CA72 | Ergotamine, combinations with psycholeptics |
| Active Ingredient | Description | |
|---|---|---|
| Dihydroergotamine |
Dihydroergotamine binds with high affinity to 5-HT1DĪ± and 5-HT1DĪ² receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors. |
|
| Ergotamine |
|
|
| Lisuride |
|
| Title | Information Source | Document Type | |
|---|---|---|---|
| MIGRANAL Nasal spray | FDA, National Drug Code (US) | MPI, US: SPL/Old |
